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Abstract
Background. As uncertainty remains about whether clinical response influences cognitive
function after electroconvulsive therapy (ECT) for depression, we examined the effect of
remission status on cognitive function in depressed patients 4 months after a course of ECT.
Method. A secondary analysis was undertaken on participants completing a randomised con-
trolled trial of ketamine augmentation of ECT for depression who were categorised by remis-
sion status (MADRS ⩽10 v. >10) 4 months after ECT. Cognition was assessed with self-rated
memory and neuropsychological tests of anterograde verbal and visual memory, autobio-
graphical memory, verbal fluency and working memory. Patients were assessed through the
study, healthy controls on a single occasion, and compared using analysis of variance.
Results. At 4-month follow-up, remitted patients (N = 18) had a mean MADRS depression
score of 3.8 (95% CI 2.2–5.4) compared with 27.2 (23.0–31.5) in non-remitted patients (N
= 19), with no significant baseline differences between the two groups. Patients were impaired
on all cognitive measures at baseline. There was no deterioration, with some measures improv-
ing, 4-months after ECT, at which time remitted patients had significantly improved self-rated
memory, anterograde verbal memory and category verbal fluency compared with those
remaining depressed. Self-rated memory correlated with category fluency and autobio-
graphical memory at follow-up.
Conclusions. We found no evidence of persistent impairment of cognition after ECT.
Achieving remission improved subjective memory and verbal memory recall, but other aspects
of cognitive function were not influenced by remission status. Self-rated memory may be use-
ful to monitor the effects of ECT on longer-term memory.
Cognitive impairment is a recognised short-term consequence of electroconvulsive therapy
(ECT) (Semkovska & McLoughlin, 2010) but controversy remains about whether or not
there is a persistent longer-term impairment (Read, Cunliffe, Jauhar, & McLoughlin, 2019;
Rose, Fleischmann, Wykes, Leese, & Bindman, 2003). Critics of ECT emphasise the subjective
experience of patients surveyed after ECT with studies finding that 29–55% of the respondents
reported persistent or permanent memory loss attributed to ECT (Rose et al., 2003). The per-
ceived potential for cognitive adverse effects is seen as a limiting factor in the use of ECT
(Finnegan & McLoughlin, 2019).
In apparent contrast to retrospective reports, a recent systematic review of subjective mem-
ory measured prospectively found that most studies reported an improvement in memory after
ECT, but noted considerable heterogeneity in both the results and in how subjective memory
was assessed (Vann & McCollum, 2019). A systematic review found that the performance on
many objective neuropsychological tests is transiently impaired by ECT but improves to base-
line or better within a few weeks after completing treatment (Semkovska & McLoughlin,
2010). More recent follow-up studies of assessing cognition a few months after ECT have
also been consistent in finding no evidence of worsening, with some domains improving, com-
pared with before ECT although the results conflict about which aspects of cognition show
improvement (Bodnar et al., 2016; Bosboom & Deijen, 2006; Mohn & Rund, 2016;
Nuninga et al., 2018; Obbels et al., 2018; Vasavada et al., 2017; Verwijk et al., 2014;
Ziegelmayer et al., 2017). A remaining area of uncertainty however is whether or not past
memories, especially autobiographical memory, might be adversely affected by ECT given
the lack of evidence (Semkovska & McLoughlin, 2010) and methodological difficulties in
the current assessment tools (Semkovska & McLoughlin, 2013). It is possible that negative sub-
jective assessment of the effect of ECT could be contributed to by loss of past memories or
impairments that are difficult to detect with standard tests (Finnegan & McLoughlin, 2019).
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Depression is itself associated with widespread impairment in
cognitive function (Pan et al., 2019) and a key issue in the assess-
ment of cognition after ECT for depression is the degree to which
mood state influences cognitive assessment results; low mood
could potentially lead to the misattribution to ECT of memory
and other cognitive problems that are in fact associated with per-
sisting depression. A further complication is that when people
recover from depression, they have cognitive impairment which
is related to the number of previous episodes (Semkovska et al.,
2019) so the experience of impaired cognitive function after
recovery from depression may be due to prior depression rather
than to the treatment received. A systematic review of subjective
memory after ECT reported the improvement following ECT cor-
related with improved depression, although there was consider-
able heterogeneity between studies (Vann & McCollum, 2019).
In contrast, those investigating objective tests of cognition have
nearly all found no relationship between performance and
mood (Bosboom & Deijen, 2006; Fernie, Bennett, Currie,
Perrin, & Reid, 2014; Maric et al., 2016; Nuninga et al., 2018;
Vasavada et al., 2017; Ziegelmayer et al., 2017). The reasons for
this discrepancy are not known but it is recognised that subjective
and objective measures of cognition often do not correlate
(Finnegan & McLoughlin, 2019), and in addition, studies of cog-
nitive test performance after ECT have been mostly statistically
underpowered and only reported mood effects incidentally.
The aim of this study was to examine the effect of mood state
on cognitive function following a course of ECT. In order to do
this, we performed a secondary analysis of cognition over time
in patients receiving ECT in a clinical trial, grouped according
to their remission status 4 months after ECT. In addition, we
compared cognition in patients to that of matched healthy con-
trols. We hypothesised that remitted patients would have better
subjective memory and objectively assessed cognition than those
who had not remitted, but that they would remain impaired com-
pared to healthy controls.
Methods
Participants
This is a secondary analysis of the Ketamine-ECT study not spe-
cified in the original trial protocol. Patients who completed the
study were grouped according to whether or not they were in
remission from depression at the final assessment 4 months
after ECT. The Ketamine-ECT study was a UK multicentre, ran-
domised, placebo-controlled trial of intravenous ketamine as an
adjunct to ECT in severely ill depressed patients that has been
previously reported (Anderson et al., 2017a, 2017b). Inclusion cri-
teria were a diagnosis of a moderate or severe major depressive
episode in unipolar or bipolar disorder by DSM-IV criteria
(American Psychiatric Association, 2000) with ECT planned as
part of clinical care, age ⩾18 years, ability to give valid consent
with a verbal IQ equivalent to ⩾85 [Wechsler Test of Adult
Reading, WTAR (Wechsler, 2001)], able to complete neuro-
psychological testing and medically fit to receive ketamine.
Main exclusion criteria were ECT in the last 3 months, detention
under the Mental Health Act (1983, amended 2007), a primary
psychotic or schizoaffective disorder, current primary obsessive–
compulsive disorder, anorexia nervosa, or history of drug or
alcohol dependence (DSM-IV criteria), organic brain disease or
significant medical illness affecting neuropsychological function,
<24 on the Mini Mental State Examination (MMSE) (Folstein,
Folstein, & McHugh, 1975), contraindication to ketamine, risk
of pregnancy or breastfeeding. Healthy controls were recruited
by advertisement and from relatives, and prospectively sex and
age group matched with patients in the main study. They were
required to be in good physical health with no history of personal,
or first-degree family, psychiatric disorder, significant medical ill-
ness, psychotropic medication or other medication that could
interfere with neuropsychological function or an MMSE <24.
The study complied with the Helsinki Declaration of 1975, as
revised in 2008. Ethical approval was granted by the North
West-Liverpool East Research Ethics Committee (Ref. 12/NW/
0021) on 25 January 2012. Clinical Trial Authorisation was
received from the UK Medicines and Healthcare products
Regulatory Agency (23148/0004/001-0001). All participants gave
written informed consent to participate. The study is registered
with the International Standard Randomised Clinical Trial
Number registry (ISRCTN14689382) and with the EU Clinical
Trial register (EudraCT number 2011-005476-41).
Study design and procedures
The Ketamine-ECT Study assessed whether ketamine given in add-
ition to ECT would improve clinical outcomes, and found it had no
effect on efficacy or cognitive function compared with saline
(Anderson et al., 2017b). Following baseline assessment, depressed
patients were randomised to intravenous ketamine 0.5mg/kg or
saline augmentation of their anaesthetic induction agents and
received ECT twice weekly based on the standard clinical ECT pro-
tocols (Royal College of Psychiatrists, 2005). Electrode placement
was predominantly bilateral (BL) with a minority receiving right
unilateral (RUL) ECT using constant-current brief pulse (0.5 ms
pulse width) stimuli to induce seizure with a treatment dose of 1.5
or 4–6 times seizure threshold for BL and RUL placement respect-
ively, determined by stimulus titration in the first session treatment.
The goal was to treat patients to remission (Montgomery–Åsberg
Depression Rating Scale, MADRS ⩽10) (National Institute for
Health and Care Excellence, 2009) but the decision to finish ECT
treatment was taken by the treating clinical team.
Cognitive assessments in patients were carried out before ECT
(baseline), after four ECT treatments, within 5 days after the end
of ECT treatment (end of ECT), and 1 and 4 months after the end
of ECT (1- and 4-month follow-up). Efficacy was assessed at base-
line, weekly during the ECT course, at the end of ECT and at the
follow-up appointments. Only results from baseline, end of ECT
and the two follow-up appointments are reported in this study.
Healthy controls were assessed on a single occasion.
Assessments
The full range of assessments is given in the main study reports
(Anderson et al., 2017a, 2017b) with those relevant presented
here. Baseline assessment included the Mini International
Neuropsychiatric Interview (Sheehan et al., 1998) to determine
diagnosis, the Massachusetts General Hospital Scale (MGHS)
(Fava, 2003) to record antidepressant drug treatment in the cur-
rent episode, the WTAR (Wechsler, 2001) as a measure of pre-
morbid intellectual functioning (IQ) and the MMSE (Folstein
et al., 1975) to screen for cognitive impairment. The key efficacy
assessment was depression severity assessed by the observer-rated
MADRS (Montgomery & Asberg, 1979).
The neuropsychological assessment consisted of tests involving
verbal and visual memory, attention and verbal fluency/executive
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function (Anderson et al., 2017a, 2017b) with the key outcomes
reported here.
Subjective memory
Self-reported Global Self Evaluation of Memory (GSE-My)
(Berman, Prudic, Brakemeier, Olfson, & Sackeim, 2008) assessed
subjective global memory and the participants’ belief about how
their memory had been affected by ECT, rated using a seven-point
bipolar scale (extremely bad/negative to extremely good/positive).
At baseline, participants were asked to rate their expectation about
how ECT would affect their memory with this time-point taken
as no effect for the analysis over time of their belief about how
ECT had affected their memory. Expectation and belief about
ECT’s effect on memory were also dichotomised as worse or no
change/better as there were very few endorsements of
improvement.
Anterograde memory and retrograde autobiographical memory
Anterograde verbal memory was measured by delayed recall on
the Hopkins Verbal Learning Test – Revised (HVLT-R-DR)
(Benedict, Schretlen, Groninger, & Brandt, 1998), which involves
learning a list of 12 words and being asked to recall as many
words as possible following an interval of 30 min. This provides
a composite test of learning, retention and ability to access the
previously learnt words. Different versions of six alternate
forms were used at each time-point in two orders of presentation.
Anterograde visual memory was assessed using delayed repro-
duction from the Medical College of Georgia Complex Figure Test
(MCGCFT) (Meador et al., 1993). The task consists of copying a
complex line drawing with multiple elements and then reprodu-
cing it from memory, immediately and after a 30 min delay.
This tests visuospatial learning, retention, retrieval and executive
planning; four alternate forms which were used at different time-
points in two orders.
The Columbia Autobiographical Memory Interview – short
form (AMI-SF) (McElhiney, Moody, & Sackeim, 1997) was used
to assess memory for personal past events; an initial interview
elicits personal memories covering six areas which are then
asked about on subsequent occasions and rated according to con-
sistency (percentage correct of the initial information provided).
Improvement over baseline cannot be measured because new or
more detailed information is not scored. A normal decline in
scores over time in both healthy participants and depressed
patients not receiving ECT has been reported using a revised scor-
ing system, but normative data are lacking for the original test
(Semkovska & McLoughlin, 2013).
Verbal fluency and working memory
The Controlled Oral Word Association Test (COWAT) (Benton,
Hamsher, & Sivan, 1994) tested letter and category fluency.
Task performance is related to the ability to update information,
a function of executive control, and verbal ability, in particular
lexical access speed for category fluency (Shao, Janse, Visser, &
Meyer, 2014). Participants were asked to generate as many
words as they could in 1 min for words starting with letters (F,
A, S) and in a given category (animals or fruit and vegetables).
The same letters were presented on subsequent tests and the
two categories were alternated in two different orders.
Digit span backwards (Wechsler, 1981) involves strings of digits
of increasing length being presented in a standard way and
the participant repeating them in reverse order. The maximum
number of digits remembered correctly is reported and is a test
of attention, working memory storage and manipulation.
Analysis
Data were analysed using IBM SPSS Statistics Version 22 (http://
www.IBM.com). At 4-month follow-up, patients were divided into
two groups categorised as being in remission (MADRS ⩽10) or
non-remitted (MADRS >10). Two patients, one in each group,
had missing data at one intermediate time-point and these were
interpolated from adjacent values. Comparisons between healthy
controls and the two groups of depressed patients were by
one-way analysis of variance (ANOVA) (with Bonferroni correc-
tion for post-hoc tests), t tests, χ2 and Mann–Whitney U tests as
applicable for parametric, non-parametric and categorical com-
parisons. Analysis of patients over time was by two-way repeated-
measures ANOVA with factors for time (assessment point) and
group (remitted, non-remitted). A drug factor (ketamine, saline)
was not included given the lack of significant effect on cognitive
outcome (Anderson et al., 2017b). Post-hoc testing was by simple
contrasts for (a) the main effect of time in all patients, and (b) the
time × group interaction to determine differential effects over time
depending on the remission group. Significance level was taken
as p < 0.05 (Huyhn–Feldt corrected for the repeated-measures
ANOVA). An exploratory correlational analysis (Spearman’s ρ)
at 4-month follow-up was used to investigate the association of
subjective memory with depression severity and task performance
given the reports of their association in the literature (Berman
et al., 2008; Vann & McCollum, 2019). Data are presented as
mean and 95% confidence interval (95% CI), or median and
interquartile range (IQR). The assessment time-points are taken
as the median time in weeks since the baseline assessment for
all patients (6, 10, 22 weeks), as values for each patient varied
according to the number of ECT treatments received.
Results
Seventy-nine patients were randomised with the 37 patients who
were assessed 4 months after the end of ECT (18 remitted, 19
non-remitted at final assessment) included in this analysis,
together with 56 healthy controls. Clinical and cognitive assess-
ments over time in the intention-to-treat patient population and
patient flow through the study are given in the main study report
(Anderson et al., 2017b) with timing and reasons for dropping
out summarised in online Supplementary Material. Patients
who dropped out were broadly similar to those completing the
study in their baseline characteristics and cognitive function
(online Supplementary Table S1). There was a wide separation
in depression scores at 4-month follow-up (Fig. 1a) with the high-
est MADRS score in the remitted group 9, and the lowest in the
non-remitted group 16. Remitted patients still scored higher than
the healthy controls (3.8, 95% CI 2.2–5.4 v. 0.8, 0.5–1.3, p = 0.045),
while the non-remitted patients remained moderately to severely
depressed (MADRS 27.2, 23.0–31.5, p < 0.001 v. healthy controls
and remitted patients). The two patient groups did not differ sig-
nificantly on demographic or illness-related measures at baseline
(Table 1). Apart from one patient in the non-remitted group, all
were on an antidepressant which was combined with an anti-
psychotic drug in just over half of patients. Most patients were
taking a selective serotonin reuptake inhibitor or serotonin and
noradrenaline reuptake inhibitor; combination antidepressant
Psychological Medicine 3
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treatment (usually with mirtazapine) occurred in five patients in
the remitted group and four in the non-remitted group.
Table 2 shows treatment-related variables. The only significant
difference was that more patients in the remitted group had remit-
ted by the end of ECT treatment than in the non-remitted group.
Non-remitted patients received non-significantly more ECT treat-
ments and hence had a slightly longer gap between baseline and
end of ECT assessment. There was only a modest change in medi-
cation which did not differ between the groups.
Baseline comparisons of mood and cognition
At baseline, the patient groups did not differ significantly from
each other or healthy controls in age, sex distribution, IQ or edu-
cation (Table 1), although patients in the non-remitted group
were a little younger with a higher proportion of men than the
other groups. Patients had higher depression scores than healthy
controls and had slightly lower MMSE scores, with impairment
on all neuropsychological tests and poorer subjective memory.
The two patient groups did not differ in depression severity or
on cognitive measures and about two-thirds expected a negative
effect of ECT on memory (see Table 1).
Change in cognitive measures over time
Subjective memory assessment
GSE-My current memory scores (Fig. 1b) showed no significant
effect of time (F3,105 = 1.363, p = 0.26) but a significant effect of
group (F1,35 = 10.003, p = 0.003) and an interaction between
group and time (F3,105 = 3.692, p = 0.02). Contrasts showed no sig-
nificant effect of ECT (time contrast between baseline and end of
ECT, p = 0.65) but a significant group × time interaction between
baseline and 4-month follow-up ( p = 0.001) and a trend between
baseline and 1-month follow-up ( p = 0.063). Non-remitted
patients did not significantly change over time, whereas remitted
patients showed improvement after ECT, with values at 1- and
4-month follow-up similar to healthy controls. In the remitted
group, 2/18 rated their memory worse at 4-month follow-up
than baseline compared with 10/19 in the non-remitted group
( p = 0.02).
Patients’ self-evaluation of the effect of ECT on the GSE-My
(Fig. 1c) showed a significant effect of time (F3,105 = 10.868, p <
0.001) and a trend to a group effect (F1,35 = 2.928, p = 0.096)
but no interaction between group and time (F3,105 = 1.300, p =
0.28). Overall patients reported a negative effect of ECT on mem-
ory which plateaued between 1- and 4-month follow-up in non-
remitters but returned towards no effect in remitters. Time con-
trasts showed this negative evaluation was significant at all time-
points compared to baseline for patients taken together ( p⩽
0.001). There were no significant group × time contrasts in keep-
ing with the overall result ANOVA (baseline compared with
4-month follow-up, p = 0.057) although the final value in remit-
ters did not significantly differ from 0 (i.e. no effect of ECT, p
= 0.3).
Of the 25 patients who expected a negative effect of ECT on
memory before ECT, 9/13 (69%) non-remitters and 4/12 (33%)
remitters reported a negative effect at follow-up; for those who
expected no effect or a positive effect, the respective figures for
a negative effect at follow-up were 3/6 (50%) and 2/6 (33%).
The differences in proportions were not significant ( p = 0.3).
Objective anterograde memory and retrograde biographical
memory
Delayed verbal memory measured with the HVLT-R-DR (Fig. 2a)
showed a significant effect of time (F3,105 = 3.425, p = 0.02) and a
trend for a group × time interaction (F3,105 = 2.490, p = 0.065).
Time contrasts showed that the slight decline in the number of
words recalled between baseline and end of ECT was not signifi-
cant ( p = 0.21), but was followed by a significant improvement
between the end of ECT and 4-month follow-up ( p = 0.02).
Remitters improved significantly compared to non-remitters
between baseline and 4-month follow-up (time × group contrast
p = 0.04) with a trend at 1-month follow-up ( p = 0.07), and did
not differ significantly from the healthy controls at both follow-up
assessments ( p > 0.5). Non-remitters remained impaired com-
pared to healthy controls at 4-month follow-up ( p < 0.01).
Fig. 1. MADRS and GSE-My ratings for the current memory and the effect of ECT over
time. Values are mean and 95%CI. Shaded area indicates 95% CI range for healthy
controls. (a) MADRS scores for patient groups illustrated based on the presence or
absence of remission at 4-month follow-up. (b) GSE-My current memory. ANOVA
group × time p = 0.02; group × time contrast between baseline and 4-month follow-up
p = 0.001. (c) GSE-My effect of ECT. ANOVA time p < 0.001, time contrasts between
baseline and subsequent time-points p⩽ 0.001.
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Delayed reproduction of a complex figure assessed with the
MCGCFT (Fig. 2b) changed significantly with time (F3,105 =
13.082, p < 0.001) with no differential effect by group (group ×
time F3,105 = 0.205, p = 0.88). Time contrasts showed a significant
decline in score after ECT compared with baseline ( p = 0.005)
and a subsequent improvement so that at 4-month follow-up, it
was significantly better than baseline, end of ECT and 1-month
follow-up ( p⩽ 0.007) and did not differ significantly from
healthy controls for either group ( p⩾ 0.12).
Retrograde autobiographical memory consistency measured by
the AMI-SF (Fig. 2c) changed significantly with time (F3,105 =
46.693, p < 0.001) with a nadir at the end of ECT and no differ-
ential effect by group (group × time F3,105 = 0.482, p = 0.69).
Time contrasts showed consistency was significantly lower than
100% at all subsequent time-points ( p < 0.001) as expected, but
significantly increased from the end of ECT to 4-month follow-up
( p = 0.005) reaching 79% and 84% in non-remitters and remit-
ters, respectively.
Verbal fluency and working memory
COWAT letter fluency (Fig. 3a) showed no effect of time (F3,105 =
1.706, p = 0.18), group (F1,35 = 0.031, p = 0.86) or group × time
interaction (F3,105 = 1.312, p = 0.28). At 4-month follow-up, both
groups produced fewer words than healthy controls, significantly
for non-remitters ( p = 0.02) but not remitters ( p = 0.19).
COWAT category fluency (Fig. 3b) changed significantly over
time (F3,105 = 3.699, p = 0.014) with a significant group × time
interaction (F3,105 = 3.874, p = 0.011). Remitters, but not non-








paMean (95% CI)b Mean (95% CI)b Mean (95% CI)b
Age 56.3 (53.1–59.5) 57.5 (51.9–63.1) 50.4 (45.3–55.4) 0.11
Sex, F:M 34:22 14:4 9:10 0.16
IQ 111 (109–114) 108 (103–114) 107 (102–113) 0.27
Years in FT education 14.6 (13.7–15.5) 14.7 (12.7–16.6) 14.0 (12.2–15.8) 0.79
MMSE 29.8 (29.6–29.9) 28.7 (27.8–29.6)** 28.7 (27.9–29.6)** <0.001
Diagnosis, UP:BP depression – 17:1 15:4 0.17
Lifetime depressive episodes – 5.9 (3.1–8.6) 6.7 (2.5–10.9) 0.72
Depression episode duration, months, Median [IQR] 7 [2 to 20] 11 [6 to 22] 0.11
MADRS 0.9 (0.5–1.3) 33.6 (29.6–37.6)*** 35.5 (31.7–39.2)*** <0.001
MGH Treatment resistance, Median [IQR] – 3.5 [2.4–4.1] 3.5 [2.5–5.0] 0.44
Previous ECT, Yes:No – 8:10 11:8 0.41
Psychotropic medication, N – 0.71
Any antidepressant 18 18
(SSRI/SNRI/TCA/other AD) (5/11/1/6) (7/7/2/6) (0.67)
Antipsychotic 11 9
Lithium 4 4
Antiepileptic drug 1 3
Hypnotic/anxiolytic 5 9
GSE-My Current global memory 4.5 (4.3–4.8) 3.7 (3.1–4.3)* 3.6 (3.0–4.2)** 0.001
GSE-My Expectation of ECT on memory, Negative:Nil/Positive – 12:6 13:6 0.91
HVLT-R Delayed recall 8.9 (8.3–9.6) 6.5 (4.7–8.4)** 7.0 (5.8–8.2)* 0.002
MCGCFT Delayed recall 25.2 (23.6–26.7) 18.2 (14.6–21.8)*** 20.3 (17.3–23.3)* <0.001
AMI-SF Baseline score – 42.8 (37.3–48.2) 48.0 (44.4–51.6) 0.10
COWAT Letter fluency 45.5 (42.4–48.7) 36.7 (30.3–43.2)* 35.7 (28.5–43.0)* 0.004
COWAT Category fluency 23.3 (22.1–24.5) 16.9 (14.3–19.5)*** 17.1 (14.6–19.7)*** <0.001
Digit span backward 4.9 (4.5–5.2) 3.4 (3.0–3.9)*** 3.7 (3.1–4.4)** <0.001
AD, antidepressant drug; AMI-SF, Columbia Autobiographical Memory Interview-Short Form; BP, bipolar; COWAT, Controlled Oral Word Association Test; ECT, electroconvulsive therapy; FT,
full-time; GSE-My, Global Self Evaluation of Memory; HVLT-R, Hopkins Verbal Learning Test-Revised; IQ, intelligence quotient; IQR, interquartile range; MADRS, Montgomery–Åsberg
Depression Rating Scale; MCGCFT, Medical College of Georgia Complex Figure Test; MGH, Massachusetts General Hospital; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and
noradrenaline reuptake inhibitor; TCA, tricyclic antidepressant; UP, unipolar.
aOne-way analysis of variance/t test/χ2/Mann–Whitney U test as applicable.
bUnless otherwise stated.
*p < 0.05, **p < 0.01, ***p < 0.001 v. healthy controls (Bonferroni corrected). No significant differences between patient groups.
Psychological Medicine 5
https://doi.org/10.1017/S0033291720000379
Downloaded from https://www.cambridge.org/core. Newcastle University, on 11 Mar 2020 at 13:28:59, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
remitters, showed an increase in the number of words produced
from the end of ECT to final assessment. Time contrasts showed
a trend decrease overall between baseline and end of ECT ( p =
0.075) and a significant increase between the end of ECT and
4-month follow-up ( p = 0.002). Remitters, compared with non-
remitters, had a significant increase from both baseline and end
of ECT to 4-month follow-up ( p⩽ 0.008). At final assessment
however, both remitters and non-remitters still performed less
well than healthy controls ( p⩽ 0.02).
Digit span backwards (Fig. 3c) showed a trend effect of time
(F3,105 = 2.153, p = 0.098), but no effect of group (F1,35 = 0.189,
p = 0.67) or group × time interaction (F3,105 = 0.872, p = 0.46).
Time contrasts showed no significant change between baseline
and end of ECT ( p = 0.14) but a greater digit span at 4-month
follow-up compared with baseline ( p = 0.049) for all patients
considered together. At 4-month follow-up, both remitters and
non-remitters were still impaired compared with healthy controls
( p⩽ 0.05).
Correlations
At 4-month follow-up, the GSE-My global memory correlated
negatively with the MADRS score (ρ =−0.56, p < 0.001) and posi-
tively with the COWAT category fluency (ρ = 0.48, p = 0.003) and
the AMI-SF percentage consistency (ρ = 0.34, p = 0.04).
Discussion
The findings of this study are in partial agreement with our
hypotheses with severely depressed patients who achieved remis-
sion 4 months after the end of a course of ECT having significant
improvements in subjective memory, anterograde verbal memory
and category (semantic) verbal fluency compared with those
remaining depressed, who did not improve compared with before
ECT. Mood status 4 months after ECT did not however influence
anterograde visual memory, autobiographical memory, letter
(phonemic) fluency or working memory. Compared to healthy
controls, remitted patients remained impaired at 4-month
follow-up with regard to working memory and category verbal
fluency but did not differ significantly on anterograde verbal
and visual memory and letter verbal fluency; however, the lack
of repeat testing in controls limits interpretation as any improve-
ment in performance due to practice effects in controls cannot be
taken into account.
Effect of ECT on cognitive function
At baseline, compared to healthy controls, depressed patients had
impaired subjective memory and impaired performance on a
range of neuropsychological tests of memory and executive func-
tion consistent with the literature (Pan et al., 2019). Following
ECT, there was a significant decrease in scores for anterograde vis-
ual memory with the shape of the time-course (a dip after ECT
with a subsequent improvement during follow-up) in keeping
with a transient negative effect of ECT. This profile was also
seen with verbal anterograde memory and category verbal fluency
(although the decrease in scores after ECT was not significant),
and autobiographical memory consistency improved after the
end of ECT. These results are consistent with a transient effect
of ECT on these measures as well, although the evidence is
weaker. In contrast, ECT did not appear to affect subjective global
memory, letter verbal fluency or working memory. While it is
possible that we missed some of the effects of ECT, as testing
occurred on average 4 days after the last ECT (Semkovska &
McLoughlin, 2010), our findings are largely consistent with the
meta-analysis by Semkovska and McLoughlin (2010) which
found ECT impaired delayed verbal and visual recall and verbal
fluency, with no significant effect on Digit span backward. Our
findings for current global memory using the GSE-My are also
similar to previous studies which have found either no effect of
Table 2. Treatment-related variables in remitted and non-remitted patients at 4-month follow-up
Measure
Remitted patients (N = 18) Non-remitted patients (N = 19)
paMean (95% CI)b Mean (95% CI)b
Number of ECT treatments 10.1 (8.1–12.2) 11.6 (9.4–13.8) 0.31
BL:RUL ECT 17:1 16:3 0.32
Received ketamine:saline 7:11 12:7 0.14
In remission at end of ECT, Yes:No 13:5 7:12 0.005
Time between baseline and end of ECT assessment, weeks 5.4 (4.5–6.3) 6.8 (5.3–8.3) p = 0.10
Time between last ECT and end of ECT assessment, days 3.8 (2.5–5.0) 3.8 (2.8–4.9) p = 0.94
Psychotropic medication at FU, N 0.41
Any antidepressant 18 18
(SSRI/SNRI/TCA/other AD) (4/13/1/5) (5/8/3/5) (0.53)
Antipsychotic 13 11
Lithium 3 6
Antiepileptic drug 0 4
Hypnotic/anxiolytic 6 10
BL, bilateral electrode placement; ECT, electroconvulsive therapy; RUL, right unilateral electrode placement; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and noradrenaline
reuptake inhibitor; TCA, tricyclic antidepressant.
at test/χ2 as applicable.
bUnless otherwise stated.
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ECT (Brakemeier, Berman, Prudic, Zwillenberg, & Sackeim, 2011)
or a modest impairment (Berman et al., 2008). Autobiographical
memory measured using the AMI-SF is more difficult to interpret
in the absence of normative data, and the decline following ECT is
similar to that reported in the absence of ECT (Semkovska &
McLoughlin, 2013). Nevertheless, relevant to our study, a rando-
mised controlled trial in depressed bipolar patients using the
AMI-SF found that immediately after ECT, there was a signifi-
cantly greater reduction in memory consistency in those rando-
mised to ECT than in those receiving pharmacotherapy only
(73% v. 81%, p = 0.025) (Kessler et al., 2014), strikingly similar
to the 75% consistency in our patients after ECT (Fig. 2c).
Impairment of retrograde amnesia immediately after ECT is
further supported by a study that showed a decline in a test of
remote memory for events in the previous year after ECT that
subsequently improved (Meeter, Murre, Janssen, Birkenhager, &
van den Broek, 2011).
Cognitive function four months after ECT
Studies examining cognitive function in the 3–6 months after
ECT have varied both in the tests employed and as to whether
or how they assess the influence of mood state. Excluding auto-
biographical memory, for which good evidence is lacking, there
is a consistent finding that cognition is at least no worse than
before treatment in the months after ECT, with some aspects
improved although the exact picture differs between studies,
and these are discussed below. For the GSE-My self-rated mem-
ory, the lack of overall change between baseline and the last
follow-up masked a significant improvement in remitters
Fig. 3. Executive function (COWAT letter and category fluency) and working memory
(Digit span backwards) over time. Values are mean and 95% CI. Shaded area indi-
cates 95% CI range for healthy controls. (a) COWAT letter fluency. ANOVA not signifi-
cant. (b) COWAT category fluency. ANOVA time p = 0.014; time contrast between the
end of ECT and 4-month follow-up p = 0.002. ANOVA group × time p = 0.011; group ×
time contrasts between baseline/end of ECT and 4-month follow-up p ⩽ 0.008. (c)
Digit span backwards. ANOVA not significant.
Fig. 2. Anterograde verbal (HVLT-R-DR) and visual (MCGCFT) memory and retrograde
autobiographical memory (AMI-SF) over time. Values are mean and 95% CI. Shaded
area indicates 95% CI range for healthy controls. (a) HVLT-R-DR. ANOVA time p = 0.02;
time contrast between the end of ECT and 4-month follow-up p = 0.02. Group × time
contrast between baseline and 4-month follow-up p = 0.04. (b) MCGCFT. ANOVA time
p < 0.001; time contrasts between baseline and end of ECT p = 0.005 and end of ECT
and 4-month follow-up p < 0.001. (c) AMI-SF. ANOVA time p < 0.001; time contrasts
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compared with non-remitters. At 4-month follow-up, subjective
memory correlated negatively with the mood in agreement with
the literature (Vann & McCollum, 2019). For delayed verbal
recall, the overall lack of significant change between baseline
and 4-month follow-up also masked an improvement in remitters
compared with no change in those still depressed. Previous stud-
ies predominantly report no overall improvement in anterograde
verbal memory in the months after ECT similar to our results
(Bosboom & Deijen, 2006; Mohn & Rund, 2016; Nuninga et al.,
2018; Vasavada et al., 2017; Verwijk et al., 2014; Ziegelmayer
et al., 2017), with one study finding an improvement (Bodnar
et al., 2016), and another an improvement on one test and not
in another (Obbels et al., 2018). Four studies examined a potential
influence of mood and found no effect in contrast to our findings
(Bosboom & Deijen, 2006; Nuninga et al., 2018; Vasavada et al.,
2017; Ziegelmayer et al., 2017), but small sample sizes mean
they lacked statistical power. Studies of category verbal fluency
at medium term follow-up after ECT have found improvement
(Mohn & Rund, 2016; Obbels et al., 2018) or no change
(Bodnar et al., 2016; Nuninga et al., 2018) with one small study
that examined the effect of mood finding no effect (Nuninga
et al., 2018). Our results show both an overall improvement in cat-
egory verbal fluency 4 months after and a clear effect of improve-
ment with remission. For letter verbal fluency, we did not find any
significant change, consistent with most (Bodnar et al., 2016;
Nuninga et al., 2018; Obbels et al., 2018), but not all (Verwijk
et al., 2014) studies, nor a difference between remitted and non-
remitted patients.
Interpretation of our results for autobiographical memory is
limited because of the AMI-SF scoring method (see Methods sec-
tion). Of note consistency improved significantly after the end of
ECT and was >80% when tested 5–6 months after baseline which
is no worse than that reported in the literature for participants not
receiving ECT (Bjoerke-Bertheussen et al., 2018; Semkovska &
McLoughlin, 2013) suggesting a probable lack of impairment.
This is also consistent with another study assessing remote mem-
ory for past events over the last year which found it had returned
to at least baseline 3 months after ECT (Meeter et al., 2011).
Nevertheless, the methodological difficulties in testing past mem-
ories experimentally make it difficult to exclude loss of specific
past memories due to ECT (Fraser, O’Carroll, & Ebmeier, 2008).
Anterograde visual memory tested by the reproduction of a
complex figure showed a different pattern to tests of verbal recall,
with an improvement in scores from baseline to 4 months after
ECT, and no evidence that it was influenced by the severity of
depression. This is consistent with the improved scores found by
most (Bodnar et al., 2016; Nuninga et al., 2018; Obbels et al.,
2018), but not all (Vasavada et al., 2017), studies, of which
none assessed the effect of mood state. The apparent improve-
ment during follow-up is likely to be due to practice effects as dis-
cussed below. Finally, we found a possible slight improvement in
Digit span backwards at final follow-up compared with baseline,
but no effect of mood, suggesting that this measure is relatively
insensitive to the current mood.
Subjective and objective cognition after ECT
Subjective rating of memory after ECT is generally reported not to
match the objective measurement on neuropsychological tests
(Finnegan & McLoughlin, 2019) with the exception of global
memory from one group using the self-rated GSE-My (Berman
et al., 2008; Brakemeier et al., 2011). We also found significant
positive correlations of the GSE-My current memory with cat-
egory verbal fluency and, less strongly, with autobiographical
memory consistency at 4-month follow-up. Of interest, both
tests require the retrieval of information in long-term memory
involving making conceptual or episodic associations. It is plaus-
ible that self-evaluation of global memory could be influenced by
being aware of how well these two aspects of long-term memory
are functioning. GSE-My global memory may therefore be a use-
ful assessment of long-term memory in clinical practice. The util-
ity of self-rated assessment of the effect of ECT is less clear given
that it was consistently more negative that self-rated memory
(Figs 1a and b) and neuropsychological task results. It is unclear
the degree to which persisting depression after ECT could con-
tribute to a negative evaluation of ECT’s effect from our results.
Other factors such as misattribution and anxiety may play a
part (Finnegan & McLoughlin, 2019), and indeed we found a
majority of patients had a negative expectation of the effect of
ECT before treatment (Table 1). It has also been suggested that
patients may be reporting subtle or patchy cognitive deficits not
picked up by routine testing when reporting the effects of ECT
(Finnegan & McLoughlin, 2019), but if so this is not reflected
in self-evaluated current global memory.
Comparison between patients and healthy controls
We only tested healthy controls on a single occasion limiting our
ability to determine how cognitive function in a patient at
follow-up compares with normal because of potential improve-
ment due to practice effects in healthy subjects, for at least some
tests (Nuninga et al., 2018; Obbels et al., 2018; Vasavada et al.,
2017). Arguably, though, subjective memory is less likely to be
affected in this way than neuropsychological tests. While we
have some confidence in baseline comparisons between patients
and controls, for follow-up assessments, this applies only when
patients performed significantly worse than controls (category
verbal fluency and working memory). In particular, the improve-
ment we found during follow-up on anterograde visual memory
tested is likely to be due to practice effects as two studies have
reported improved performance on a delayed complex figure
task in healthy controls when repeated (Nuninga et al., 2018;
Vasavada et al., 2017), although whether practice effects occur
to the same extent in ECT-treated depressed patients is uncertain.
While medication effects cannot be excluded as a cause of impair-
ment, our results are broadly consistent with the deficits reported
more generally in patients remitted from depression (Semkovska
et al., 2019).
Strengths and limitations
This study contributes data to the important issue of cognitive
functioning in the months after ECT. A strength of the study
includes a prospective assessment of well-defined patient groups
with a wide separation in depression severity at final follow-up,
in the absence of systematic demographic or baseline differences.
The low MADRS score in the remitted group indicates a high
level of symptomatic recovery, similar to that seen in a commu-
nity sample (Anderson et al., 2011). Important limitations include
a secondary data analysis not planned in the original study design,
with a relatively small sample size, which means the results need
to be interpreted with caution. Included patients were required to
have a reasonable cognitive function so it is not possible to
extrapolate to cognitively impaired patients receiving ECT.
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There was a substantial drop out of patients by final follow-up
making generalisation to the whole population uncertain,
although at baseline, completers did not substantially differ
from those dropping out (online Supplementary Table S1). The
range of tasks was restricted to allow testing in a severely ill popu-
lation, assessment of executive function was limited and we can-
not comment on cognition beyond 4 months after ECT. We
cannot exclude the potential adverse effects of medication on cog-
nition in patients, but the similarity between the two patient
groups makes this unlikely to explain the differences found
between them. Healthy volunteers were only tested on one occa-
sion so we lacked comparison data for autobiographical memory
and did not have data on how performance might have improved
due to practice effects for comparison with patients at follow-up.
Conclusions
We found no evidence for persistent cognitive deficits occurring
as a result of ECT and were able to provide evidence of the
importance of remission on the degree of improvement of sub-
jective memory and some aspects of neuropsychological test per-
formance up to 4 months after ECT. For the latter, a benefit for
remission was evident for anterograde verbal memory and cat-
egory verbal fluency, which involve episodic and semantic verbal
recall, respectively. We confirmed the importance of remission on
improving self-reported memory measured by the GSE-My with
preliminary evidence that this subjective measure is related to
aspects of long-term memory performance, suggesting that it
may be useful clinically to assess memory before and after ECT.
Remitted patients 4 months after ECT still had cognitive deficits
compared with healthy controls consistent with those reported in
the literature. These deficits have been shown to contribute to
functional impairment (Woo, Rosenblat, Kakar, Bahk, &
McIntyre, 2016), suggesting that symptom relief alone is unlikely
to restore full functional recovery in depressed patients.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291720000379.
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